1421330-83-7

Basic information

• Product Name: C₁₂H₁₁Br₃N₂O₂
• Synonyms: C₁₂H₁₁Br₃N₂O₂
• CAS NO: 1421330-83-7
• Molecular Weight: 454.944
• Mol File: 1421330-83-7.mol

Chemical Properties

• CAS DataBase Reference: C₁₂H₁₁Br₃N₂O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₂H₁₁Br₃N₂O₂(1421330-83-7)
• EPA Substance Registry System: C₁₂H₁₁Br₃N₂O₂(1421330-83-7)

Safety Data

• Hazardous Substances Data: 1421330-83-7(Hazardous Substances Data)

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 1421330-76-8 C₁₀H₁₀Br₂N₂O 
• 124771-56-8 (E)-4-(3,5-Dibromo-2-hydroxy-phenyl)-but-3-en-2-one 
• 90-59-5 3,5-Dibromosalicylaldehyde 
• 598-72-1 2-Bromopropionic acid 

Relevant articles and documents

Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors

BuChE inhibitors play important roles in treatment of patients with advanced Alzheimer's disease (AD). A series of tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one derivatives were synthesized and evaluated as acetylcholinesterase (AChE) and butyrylch

Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors

Thirty seven novel 2-pyrazoline-1-ethanone derivatives were designed, synthesized and evaluated as selective hMAO inhibitors. Among them, compounds 7h (IC50 = 2.40 μM) and 12c (IC50 = 2.00 μM) exhibited best inhibitory activity and selectivity against hMAO-A, surpassing that of the positive control Clorgyline (IC50 = 2.76 μM). Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3) > piperidinyl (4) > morpholinyl (5) > imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity. Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively. In addition, the substituent at C3 position of 2-pyrazoline with the N1 acetyl has little effect on MAO-A inhibitory activity. These data support further studies to assess rational design of more efficiently selective hMAO inhibitors in the future.

Novel coumarin-dihydropyrazole thio-ethanone derivatives: Design, synthesis and anticancer activity

A series novel 1-(3-substituted-5-phenyl-4,5-dihydropyrazol-1-yl)-2-thio- ethanone derivatives as potential telomerase inhibitors were designed and synthesized. The bioassays demonstrated that compounds 4a, 4f, 4j and 7b, 7d occupied high antiproliferative activity against SGC-7901, MGC-803, Bcap-37 and HEPG-2 cell lines. By a modified TRAP assay, some title compounds were tested against telomerase, and compound 4f showed the most potent inhibitory activity with IC50 value at 0.92 ± 0.09 μM. The mechanism of antitumor action indicated that title compounds 4f and 7b could suppress cell proliferation through inducing cell cycle arrest in G0/G1 phase.

Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5- tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors

Eight novel 4,5-tetrahydropyrazolo[1,5-d][1,4]oxazepine derivatives have been synthesized and purified to be screened for anticancer activity. By a modified TRAP assay, some titled compounds were tested against telomerase, and compound 4a showed the most potent inhibitory activity with IC50 value at 0.78 ± 0.22 μM. Western blot assays showed that compounds 4a and 4b could inhibit expression of Cyclin D1, TERT, phospho-AKT and PI3K/AKT pathway.